

## Lipum Q4 - Boosted by positive clinical results

Redeye provides a research update following the Q4 report published by Lipum earlier today. While the company reported OPEX above our expectation following preparations ahead of the upcoming phase II trials, the focus is undoubtedly on the recent positive phase I topline results. We are encouraged to learn that the candidate demonstrated a robust safety and tolerability profile, predictable pharmacokinetics and successful suppression of the target protein (BSSL).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Lipum Q4 - Boosted by positive clinical results](#)